Disease-modifying therapies and Coronavirus disease

This study was undertaken to assess the impact of immunosuppressive and immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID‐19) in people with multiple sclerosis (PwMS).

This study was undertaken to assess the impact of immunosuppressive and immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID‐19) in people with multiple sclerosis (PwMS).

We retrospectively collected data of PwMS with suspected or confirmed COVID‐19. All the patients had complete follow‐up to death or recovery. Severe COVID‐19 was defined by a 3‐level variable: mild disease not requiring hospitalization versus pneumonia or hospitalization versus intensive care unit (ICU) admission or death. We evaluated baseline characteristics and MS therapies associated with severe COVID‐19 by multivariate and propensity score (PS)‐weighted ordinal logistic models. Sensitivity analyses were run to confirm the results.

Of 844 PwMS with suspected (n = 565) or confirmed (n = 279) COVID‐19, 13 (1.54%) died; 11 of them were in a progressive MS phase, and 8 were without any therapy. Thirty‐eight (4.5%) were admitted to an ICU; 99 (11.7%) had radiologically documented pneumonia; 96 (11.4%) were hospitalized.

After adjusting for region, age, sex, progressive MS course, Expanded Disability Status Scale, disease duration, body mass index, comorbidities, and recent methylprednisolone use, therapy with an anti‐CD20 agent (ocrelizumab or rituximab) was significantly associated (odds ratio [OR] = 2.37, 95% confidence interval [CI] = 1.18–4.74, p = 0.015) with increased risk of severe COVID‐19. Recent use (<1 month) of methylprednisolone was also associated with a worse outcome (OR = 5.24, 95% CI = 2.20–12.53, p = 0.001). Results were confirmed by the PS‐weighted analysis and by all the sensitivity analyses.

This study showed an acceptable level of safety of therapies with a broad array of mechanisms of action. However, some specific elements of risk emerged. These will need to be considered while the COVID‐19 pandemic persists. ANN NEUROL 2021;89:780–789

The COVID‐19 pandemic and the many questions about the postpandemic period complicate the management of patients who need therapies that impact on the immune system. Data available so far are overall reassuring, excluding major safety issues.1-4 However, the robustness of results is not optimal due to the relatively small samples, collected in a situation of urgency. Furthermore, for most of the autoimmune diseases, many possible therapies are available, thus increasing the heterogeneity of the datasets. It is therefore necessary to rely on larger and better characterized case series to improve data quality and relevance. The results will inform clinical decisions that will have a long‐term impact, given the chronicity of the diseases, the duration of therapies, and the long‐lasting effects of some treatments.

Multiple sclerosis (MS) is the major cause of neurological disability in young adults, with approximately 2.3 million people affected worldwide.5 Up to 70% of people with MS (PwMS) are treated with disease‐modifying therapies (DMTs) that impact on the immune response and may carry an increased probability of infection.6 This risk must be balanced against the consequences of poorly controlled MS. Hence, reliably assessing the risk of coronavirus disease 2019 (COVID‐19) in these patients is an important public health issue, and more data are needed to guide clinical practice, as pointed out in recent reviews.7 So far, the largest study based on data is the paper on the French cohort,3 but the sample size did not allow drawing conclusions about the association of DMTs and COVID‐19 severity.

We present the results of an observational study on PwMS with a confirmed or suspected COVID‐19 infection, based on clinician‐reported data. The study was conducted in Italy, a high‐prevalence area for MS8 that was the first European country to suffer the effects of the pandemic. The results are presented after the preplanned sample size needed to reach conclusions on the effect of DMTs on COVID‐19 severity was reached.

Patients and Methods
Data Sources
We obtained clinician‐reported demographic and clinical data on PwMS with a confirmed or suspected COVID‐19 infection from 85 Italian MS centers (Supplementary Table S2). We used a common web‐based electronic case report form (eCRF) to collect the data and a unified protocol to analyze them. Data were obtained after data‐sharing agreements between the Italian MS Society, the Italian Neurological Society, the University of Genoa, and all the MS centers involved. Demographic, MS history, COVID‐19 infection, and follow‐up data were collected. The study was approved by the regional ethics committee of Liguria (University of Genoa; n 130/2020–DB id 10433) and at a national level by the Italian Medicines Agency.

Study Population
We included adult MS patients who had been in contact with their neurologist because of a confirmed or suspected infection by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) during the observation period (January 15 to September 10, 2020). The confirmed cases were those with a positive test (reverse transcriptase polymerase chain reaction on nasal and pharyngeal swabs) for SARS‐CoV‐2 or a positive serological test obtained at any point during the observation period; the suspected cases were those who had radiological findings or symptoms highly suggestive of SARS‐CoV‐2 infection, according to medical judgment (cough, fever, shortness of breath, sudden onset of anosmia, ageusia, dysgeusia), and/or had close contact with a confirmed COVID‐19 case in the 14 days prior to the onset of symptoms. Data were collected retrospectively from the first contact until an outcome (death or recovery), taking as baseline the day of symptoms appearance. The first contact was a hospital visit, a phone call, or a web‐based visit, upon patients’ or clinicians’ request. Clinicians collected data by reviewing patients’ clinical charts.

Variables Assessed
Collected data are detailed in the eCRF. We collected demographic data, including age, sex, body mass index (BMI), patient‐reported race and ethnic group, work status, number of cohabitants and number of cohabitants positive for SARS‐CoV‐2 infection, patient‐reported smoking and drinking status, and comorbidities; MS history data, including type of MS (relapsing–remitting MS [RRMS], primary progressive, or secondary progressive), disease onset date, Expanded Disability Status Scale (EDSS), DMTs at the date of symptoms start, and date of last treatment dose; and COVID‐19 infection data, including suspected geographic area of infection, symptoms, laboratory and radiological data, hospitalization, pneumonia and severity of pneumonia according to radiological examinations and ventilation support, therapies for COVID‐19, intensive care unit (ICU) admission, and recovery or death.

Each week a query for follow up update was sent to all centers, until they filled the outcome report (death or recovery).

End Points
We run 2 main analyses on the following primary endpoints: (1) observed number of deaths over the whole follow‐up; and (2) severe COVID‐19 characterized by a 3‐level variable; the highest severity level was death or ICU admission, the intermediate severity level was diagnosis of pneumonia or hospitalization, and the lowest severity level was a milder disease with no need for hospitalization or documented diagnosis of pneumonia.

Statistical Analysis
The web‐based data collection started on March 1, 2020 and closed for the analysis on September 10, 2020. The first date of symptom appearance retrospectively reported was January 15, 2020. All the patients had complete follow‐up to death or recovery.

For the sample size calculations, we determined that 800 patients were needed, assuming a rate of severe outcomes (death, ICU admission, pneumonia, or hospitalization) of 20% in the reference group and a comparison group made of 15% of the full cohort, to have a power of 90% to detect an increased risk of severe outcome in the comparison group quantified by an odds ratio (OR) = 2.0 at a confidence level of 0.05.

To make efficient use of the available data, we used multiple imputation of missing values for missing baseline data. Imputation was performed using chained equations,9 where each incomplete variable is imputed by a separate model and implemented trough the “mice” R package. Continuous variables (age, height, weight, BMI, and disease duration) were parameterized as numeric data and imputed with the predictive mean matching method, whereas polytomous logistic regression was used for the unordered categorical variables (such as MS phenotype). EDSS and disease duration were used to impute the MS phenotype; age and MS phenotype were used to impute disease duration; age, height, or weight was used to impute BMI.

To assess risk factors at symptoms onset for a severe disease course, we ran a multivariate ordinal logistic regression assuming proportional ORs with severe outcome (defined as a 3‐level factor) as the dependent variable, after assessing that the assumptions of proportional odds were satisfied. The ORs reflect the multiplicative change in the odds of being at a higher level of the dependent variable for every one‐unit increase of the independent variable. The multivariate model included age, sex, BMI, EDSS, disease duration, MS disease phase (RRMS vs progressive), presence of comorbidities, methylprednisolone use within 1 month since COVID‐19 symptoms onset, and DMT class as independent variables, stratified by macroregion (defined as Lombardy; Northern Italy, including Piedmont, Veneto, Emilia‐Romagna, and Liguria; and the rest of Italy). DMT class was coded as an 8‐level variable as no therapy, interferon, glatiramer‐acetate, teriflunomide, dimethyl fumarate, natalizumab, anti‐CD20 (rituximab or ocrelizumab), or other. Alemtuzumab and cladribine were grouped in the “other” group, because the number of patients in these two therapeutic arms was too low to draw meaningful conclusions. “No therapy” was used as the reference category. We also ran the same ordinal logistic analysis after a multinomial propensity score (PS) weighting, as an alternative method to balance the differences of baseline characteristics among patients treated with different DMTs. The weights were calculated using an iterative robust approach based on the Generalized Boosted Model (GBM).10 The balance among treatment groups was defined by the standardized mean difference, and the optimal GBM iteration was found by minimizing this quantity.

Results were also presented taking dimethyl fumarate, which is the most frequently used therapy in Italy, as the reference therapy group (Supplementary Appendix). Additional analyses were focused on the anti‐CD20 therapies using the same multivariate ordinal logistic model adjusted for all the baseline variables; we investigated the effect of being on anti‐CD20 versus not being on anti‐CD20, the effect of the distance from last infusion (0–3 months, >3 months), and the effect of the time since therapy start (<6 months, 6–12 months, >12 months).

Sensitivity analyses were run by repeating all the analyses on the subgroup of confirmed cases only, in the subgroup of patients with a RRMS course, in a model including only patients with complete baseline data with no imputation and using a leave one out procedure rerunning the analysis excluding one of the 3 major centers (Brescia, Bergamo, Milan) at a time (Supplementary Appendix).

Role of the Funding Source
Roche donated the web‐based platform for data collection. Roche did not have any role in study design; in analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.

Patients Characteristics
On September 10, 844 PwMS with complete follow‐up from first contact to the outcome (recovery or death) from 85 centers were included in the dataset (Supplementary Appendix). Thirty‐four percent (286/844) of patients were from 3 centers in Lombardy (ASST Spedali Civili, Brescia‐Montichiari; Papa Giovanni XXIII Hospital, Bergamo; and San Raffaele Hospital, Milan); the distribution of patients by region is shown in Supplementary Table S3.

Table 1 reports the baseline demographic and clinical characteristics of the cohort. The mean age was 45 years (range = 18–82), the percentage of females was 70.3%, the median EDSS was 2 (interquartile range [IQR] = 1.50–4), and the proportion of progressive patients was 16%. Six hundred ninety‐three (82%) patients were treated with a DMT at the time of COVID‐19 presumed symptoms onset.

TABLE 1. Baseline Demographic and Clinical Characteristics of Included Patients

CharacteristicOverall, N = 844Suspected, n = 565Confirmed, n = 279
Age, n (%)
<40 yr279 (33.1)203 (35.9)76 (27.2)
40–59 yr471 (55.8)312 (55.2)159 (57.0)
60–79 yr92 (10.9)50 (8.8)42 (15.1)
≥80 yr2 (0.2)0 (0.0)2 (0.7)
Female sex, n (%)593 (70.3)410 (72.6)183 (65.6)
BMI, mean (SD)23.82 (4.37)23.61 (4.37)24.28 (4.37)
Comorbidities, n (%)188 (22.3)115 (20.4)73 (26.2)
MS phenotype, n (%)
Primary progressive44 (5.2)24 (4.2)20 (7.2)
Relapsing–remitting676 (80.1)469 (83.0)207 (74.2)
Secondary progressive91 (10.8)46 (8.1)45 (16.1)
Missing data33 (3.9)26 (4.6)7 (2.5)
MS disease duration, median (IQR)10.2 (4.7–17.1)9.6 (4.3–16.2)11.8 (5.4–18.5)
EDSS, median (IQR)2 (1.50–4)2 (1.50–3.50)2 (1.50–4)
MS treatment, n (%)
Dimethyl fumarate174 (20.6)131 (23.2)43 (15.4)
Fingolimod94 (11.1)59 (10.4)35 (12.5)
Ocrelizumab89 (10.5)58 (10.3)31 (11.1)
Natalizumab85 (10.1)51 (9.0)34 (12.2)
Interferon73 (8.6)52 (9.2)21 (7.5)
Copaxone70 (8.3)52 (9.2)18 (6.5)
Teriflunomide64 (7.6)37 (6.5)27 (9.7)
Alemtuzumab14 (1.7)11 (1.9)3 (1.1)
Cladribine11 (1.3)7 (1.2)4 (1.4)
Azathioprine10 (1.2)4 (0.7)6 (2.2)
Rituximab5 (0.6)4 (0.7)1 (0.4)
Methotrexate1 (0.1)1 (0.2)0 (0.0)
Mitoxantrone1 (0.1)1 (0.2)0 (0.0)
Other2 (0.2)2 (0.4)0 (0.0)
None151 (17.9)95 (16.8)56 (20.1)
Previous methylprednisolone, n (%)26 (3.1)16 (2.8)10 (3.6)

BMI = body mass index; EDSS = Expanded Disability Status Scale; IQR = interquartile range; MS = multiple sclerosis; SD = standard deviation.
Three hundred eighty‐four patients (45.5%) had at least one laboratory test executed for the COVID‐19 diagnosis; 307 (36.4%) patients were tested in the active phase with a swab and 127 (15.0%) had a serological test after recovery. Overall, 279 (33.1%) were classified as confirmed cases. Because the test during the pandemic peak was done only in the most severe patients, confirmed cases are expected to be more severe than suspected cases. In the confirmed cases subgroup, there was a higher proportion of older subjects than in the suspected cases subgroup (>60 years = 16% vs 9%) and more patients in the progressive MS phase (23% vs 12%).

The baseline characteristics of the cohort according to DMT received are reported in Table 2; patients with no therapy were older (mean age = 53.4 years), with a higher EDSS (mean EDSS = 5.5) and with a higher proportion of progressive patients (45.7%) than patients treated with DMTs. Among treated patients, those treated with interferon, glatiramer‐acetate, or teriflunomide were older than those in other DMT groups, and patients treated with anti‐CD20 had a higher EDSS (mean EDSS = 3) and a larger portion of progressive patients (25.6%) than those treated with other DMTs, but not larger than the untreated group.

TABLE 2. Baseline Demographic and Clinical Characteristics of Included Patients according to Disease‐Modifying Therapy Received

CharacteristicNo Therapy, n = 151IFN, n = 73GA, n = 70Teri, n = 64DMF, n = 174FTY, n = 94Nat, n = 85Anti‐CD20, n = 94aOther, n = 39
Age, mean (SD)53.4 (13.4)47.5 (10.5)45.7 (11.3)49.1 (9.4)41.4 (10.9)44.2 (9.5)37.9 (9.8)42.0 (10.0)42.2 (13.8)
Female sex, n (%)104 (68.9)53 (72.6)48 (68.6)44 (68.8)114 (65.5)74 (78.7)64 (75.3)64 (68.1)28 (71.8)
BMI, mean (SD)24.6 (4.6)24.3 (2.7)25.2 (5.0)24.7 (4.5)23.3 (4.1)23.9 (5.2)22.7 (4.1)22.6 (3.7)23.2 (3.8)
MS phenotype, n (%)
Primary progressive22 (14.6)0 (0.0)1 (1.4)0 (0.0)0 (0.0)2 (2.1)1 (1.2)16 (17.0)2 (5.1)
Relapsing–remitting65 (43.0)65 (89.0)64 (91.4)59 (92.2)165 (94.8)81 (86.2)83 (97.6)67 (71.3)27 (69.2)
Secondary progressive47 (31.1)6 (8.2)2 (2.9)3 (4.7)5 (2.9)9 (9.6)0 (0.0)9 (9.6)10 (25.6)
Missing data17 (11.3)2 (2.7)3 (4.3)2 (3.1)4 (2.3)2 (2.1)1 (1.2)2 (2.1)0 (0.0)
MS disease duration, median yr (IQR)16.2 (8–23)12.0 (6–19)10.1 (5–17)11.4 (6–15)5.5 (3–13)11.8 (7–18)9.1 (5–15)8.2 (4–13)12.9 (5–18)
EDSS, median (IQR)5.5 (2–7)1.5 (1–2.5)1.5 (1–2)2.0 (1.5–3)1.5 (1–2)2.0 (1.5–3)2.0 (1.5–3)3.0 (1.5–4.5)3.0 (1.5–6)
Methylprednisolone,b n (%)9 (6.0)2 (2.7)1 (1.4)2 (3.1)4 (2.3)4 (4.3)1 (1.2)1 (1.1)2 (5.1)

a Ocrelizumab or rituximab.
b One month before symptoms onset.
BMI = body mass index; DMF = dimethyl fumarate; EDSS = Expanded Disability Status Scale; FTY = fingolimod; GA = glatiramer‐acetate; IFN = interferon; IQR = interquartile range; MS = multiple sclerosis; Nat = natalizumab; SD = standard deviation; Teri = teriflunomide.
Thirteen (1.54%) patients died, and their characteristics are described in Table 3; 8 of them were PwMS with no therapy, all in a progressive disease phase (1 primary progressive MS, 7 secondary progressive MS). Five of them were treated (rituximab, ocrelizumab, natalizumab, glatiramer‐acetate, dimethyl fumarate), and only 2 of them were in a RRMS phase (glatiramer‐acetate and natalizumab). The mean time from symptoms to death was 18 days (range = 5–54 days).

TABLE 3. Characteristics of Deceased Patients

Sex, Age, yrDisease DurationDisease PhaseEDSSTherapyComorbidities
M, 6333SPMS7No therapyDiabetes
M, 672PPMS7.5No therapyCHD, hypertension, HBV
M, 6821SPMS6Dimethyl fumarateCerebrovascular disease, hypertension, depression, TBC
F, 5720SPMS9No therapyNo
M, 7617SPMS6.5No therapyCHD, hypertension, depression, dyslipidemia
F, 521RRMS5NatalizumabNo
F, 5027SPMS6OcrelizumabNo
M, 5933SPMS9No therapyNo
F, 6819SPMS5.5No therapyNo
F, 5420SPMS7RituximabNo
M, 6410RRMS2Glatiramer‐acetateNo
M, 6333SPMS6.5No therapyDiabetes, bipolar disorder
M, 6030SPMS9No therapyHypertension, cerebrovascular disease, CHD

CHD = coronary heart disease; F = female; HBV = hepatitis B virus; M = male; PPMS = primary progressive multiple sclerosis; RRMS = relapsing–remitting multiple sclerosis; SPMS = secondary progressive multiple sclerosis; TBC = tuberculosis.

Risk Factors for a Severe COVID‐19 Outcome
Thirty‐eight (4.5%) patients were admitted to an ICU (7 of them died); 99 cases (11.7%) of radiologically documented pneumonia were reported; 96 patients (11.4%) were hospitalized. Forty‐four patients (5.2%) were in the highest severity class (death or ICU admission), and 92 patients (10.9%) were in the intermediate severity class (pneumonia or hospitalization). Twenty‐six patients (3.1%) received methylprednisolone in the month preceding the first symptoms of COVID‐19.

Risk factors for severe COVID‐19 in univariate, multivariate, and PS‐weighted analysis are reported in Table 4. The assumptions of proportional odds were satisfied. Older age, male sex, higher EDSS, longer MS duration, presence of comorbidities, and progressive MS course were all risk factors for a more severe disease in univariate analysis. Methylprednisolone use within 1 month before COVID‐19 symptoms onset was associated with increased risk (OR = 3.38, 95% confidence interval [CI] = 1.49–7.67, p = 0.004). Taking no therapy as the reference category indicated a reduced risk for all the DMTs, with OR ranging from 0.34 to 0.50, except for the anti‐CD20 therapies (ocrelizumab/rituximab, OR = 0.94). When adjusting the OR in the multivariate model, the risk factors with a significant impact on COVID‐19 severity were age, sex, EDSS, recent use of methylprednisolone, and anti‐CD20 therapy. Age and EDSS fully explained the apparent risk associated with no therapy as compared to the other DMTs, and the only treatment associated with a higher risk of a severe COVID‐19 disease was anti‐CD20 therapy (OR = 2.37, 95% CI = 1.18–4.74, p = 0.015). Also, the increased risk associated with the use of recent methylprednisolone was confirmed (OR = 5.24, 95% CI = 2.20–12.53, p = 0.001). The PS‐weighted characteristics of patients according to the different DMTs received are reported in Supplementary Table S11. The DMT effects on COVID‐19 severity are replicated by the PS‐weighted analysis. The OR for anti‐CD20 therapy was 3.91 (95% CI = 1.71–8.91, p = 0.001).

TABLE 4. Univariate, Multivariate, and PS‐Weighted Ordinal Logistic Regression Models Evaluating Risk Factors for Severe Coronavirus Disease 2019a

Univariate Analysis, n = 844bOR (95% CI)                                ⁄      pMultivariate Analysis, n = 844bOR (95% CI)                                ⁄      pPS Analysis, n = 844bOR (95% CI)                                     ⁄      p
Age, yr1.06 (1.04–1.08)<0.0011.06 (1.03–1.08)<0.0011.06 (1.03–1.10)0.001
Sex, F vs M0.64 (0.40–1.03)0.0680.69 (0.45–1.04)0.0760.83 (0.50–1.39)0.49
Progressive vs RRMS4.14 (2.70–6.35)<0.0011.59 (0.81–3.01)0.181.76 (0.70–4.40)0.23
EDSS1.33 (1.22–1.45)<0.0011.07 (0.93–1.22)0.401.08 (0.86–1.35)0.50
Disease duration, yr1.04 (1.02–1.06)<0.0111.00 (0.98–1.03)0.990.99 (0.96–1.02)0.57
BMI1.01 (0.97–1.05)0.530.98 (0.94–1.02)0.440.99 (0.93–1.02)0.74
Comorbidities, yes1.70 (1.13–2.56)0.0120.93 (0.58–1.47)0.740.82 (0.48–1.42)0.48
Methylprednisolonec3.38 (1.49–7.67)0.0045.24 (2.20–12.53)0.0012.51 (0.99–6.44)0.05
No therapyd1 (ref)1 (ref)1 (ref)
Interferon0.35 (0.15–0.79)0.0120.67 (0.28–1.65)0.390.71 (0.29–1.78)0.48
Glatiramer‐acetate0.34 (0.14–0.81)0.0150.77 (0.29–2.00)0.591.19 (0.30–4.87)0.80
Teriflunomide0.48 (0.21–1.07)0.070.86 (0.36–2.08)0.741.17 (0.41–3.63)0.76
Dimethyl fumarate0.38 (0.20–0.70)0.0021.12 (0.55–2.30)0.751.29 (0.58–2.87)0.62
Natalizumab0.35 (0.16–0.76)0.0091.30 (0.53–3.22)0.571.77 (0.61–5.07)0.29
Fingolimod0.50 (0.26–0.98)0.041.19 (0.57–2.52)0.641.48 (0.66–3.34)0.34
Anti‐CD20e0.94 (0.52–1.08)0.852.37 (1.18–4.74)0.0153.91 (1.71–8.91)0.001
Other0.38 (0.14–1.04)0.060.71 (0.28–2.65)0.391.50 (0.40–5.71)0.55

a Intensive care unit or death vs hospitalization or pneumonia vs milder symptoms not requiring hospitalization and no documented pneumonia.
b All the analyses are adjusted for macroregion (Lombardy; Northern Italy, including Veneto, Emilia‐Romagna, Piedmont, and Liguria; and the rest of Italy).
c One month before symptoms onset.
d No therapy was chosen as the reference class.
e Ocrelizumab or rituximab.
BMI = body mass index; CI = confidence interval; DMT = disease‐modifying therapy; EDSS = Expanded Disability Status Scale; F = female; M = male; OR = odds ratio; PS = propensity score; RRMS = relapsing–remitting multiple sclerosis.

The results taking dimethyl fumarate as the reference category are reported in the Supplementary Appendix and are in line with the above results. All the sensitivity analyses confirmed these findings; the anti‐CD20–treated patients had an OR = 2.62 (p = 0.05) in the subgroup of confirmed cases, an OR = 2.87 (p = 0.03) in the subgroup of RRMS patients, and an OR = 2.69 (p = 0.026) using only complete baseline data with no imputation (Supplementary Appendix).

A further result that deserves attention is the risk reduction observed in patients treated with interferon (OR = 0.67); however, this does not reach a statistical significance. Among the 73 patients on interferon, no ICU admissions or deaths were recorded.

To give an idea of the absolute risk of severe COVID‐19 according to DMT, Figure 1 reports the percentage of patients with severe events (pneumonia, hospitalization, ICU, or death) in the group treated with anti‐CD20, in the untreated group, and in the group treated with other DMTs. To adjust these values for the confounding factors, the figure was restricted to patients <65 years old and with EDSS < 6.5 (n = 733), and presented separately for the RRMS (n = 675) and progressive MS (n = 58) groups. The percentage of subjects with severe events was higher in the group of patients treated with anti‐CD20 both in the RRMS and in the progressive MS patients; in the RRMS group, the proportion of patients deceased or admitted to ICU in the anti‐CD20 group was 6.1%, versus 4.2% in the untreated and 2.2% in the other DMTs group. In the progressive MS group, it was 12.5% in the anti‐CD20 group, 10.5% in the untreated group, and 4.3% in the other DMTs group. The percentage of patients with an intermediate severity (pneumonia or hospitalization) had the same trend of increase in the anti‐CD20 group.



Percentage of patients with pneumonia/hospitalization and intensive care unit (ICU)/death in the subgroup of subjects with age < 65 years and Expanded Disability Status Scale < 6.5, according to multiple sclerosis (MS) phenotype (relapsing–remitting vs progressive MS), in the anti‐CD20, no therapy, and other therapies groups. DMT = disease‐modifying therapy.
The increase of risk associated with anti‐CD20 was maintained on hard end points (death or ICU admission), even if the small number of events did not allow this to reach statistical significance (Supplementary Appendix).

The adjusted OR for anti‐CD20 therapy versus all the other therapies was 2.37 (95% CI = 1.36–4.12, p = 0.002). Exploratory analyses revealed no association between COVID‐19 severity and the time passed since the last anti‐CD20 infusion (OR = 2.77, 95% CI = 1.31–5.89, p = 0.012 for last infusion within 3 months and OR = 2.05, 95% CI = 0.97–4.28, p = 0.023 for last infusion before 3 months), whereas there was a trend with therapy duration; as compared to PwMS treated with other therapies, patients on anti‐CD20 therapy for <6 months had an OR = 1.65 (95% CI = 0.56–4.90, p = 0.36), patients on anti‐CD20 therapy for 6–12 months had an OR = 2.24 (95% CI = 0.91–5.55, p = 0.08), and patients on anti‐CD20 therapy for >12 months had an OR = 2.98 (95% CI = 1.37–6.46, p = 0.006; Supplementary Appendix).

No severe outcomes (no pneumonia, hospitalization, ICU, or death) were observed in the 11 patients treated with cladribine or in the 14 patients treated with alemtuzumab.

This study shows an acceptable level of safety of immunomodulatory and immunosuppressive therapies in MS during the COVID‐19 pandemic. However, two results deserve attention.

First, 11 of 13 deaths occurred in persons with advanced disease and disability (median EDSS = 7). The median age of people who died was 63 years versus a median age of 45 years for those who recovered. Higher EDSS was associated in multivariate analysis with COVID‐19 severity also in the French MS population.3 These findings strengthen the need to enforce prevention strategies for people with advanced disability and older age during the pandemic.11

Second, we observed an increased frequency of a severe COVID‐19 in people treated with anti‐CD20 therapies compared to other DMTs. Smaller case series suggested an increased susceptibility to COVID‐19 in PwMS taking B‐cell–depleting monoclonal antibodies,12-14 without major effects on the severity of COVID‐19.13-15 In the largest study published so far (the French study), DMT exposure was not included in the multivariate model. The results of the univariate analysis are very similar to those presented here.3 It will be informative to evaluate the OR for the impact of DMTs on severity in the French cohort in the multivariate model, to check the size of effect, irrespective of the statistical significance. Data are available about the general risk of infections during DMTs for MS; a nationwide Swedish cohort examined the infection risks in PwMS treated with DMTs.16 In that study, rituximab was associated with the highest rate of serious infections. However, the use of herpes antivirals was lower with rituximab compared to fingolimod and natalizumab; ocrelizumab clinical trials reported an increased risk of respiratory tract infections,17, 18 and safety issues emerged in diseases other than MS.19 With respect to the association with treatment duration, it has been shown that long‐term anti‐CD20 treatment is associated with the risk of hypogammaglobulinemia in neuromyelitis optica‐spectrum disorder.20 A protracted treatment may impact on the protective, anti–SARS‐CoV‐2 humoral response21 and on a pre‐existing humoral and cellular immune repertoire, recently described in unexposed individuals.22, 23

We did not observe a link between time to last infusion of ocrelizumab and COVID‐19 risk. This preliminary result needs to be confirmed, but it is consistent with the idea that the immunological effects of ocrelizumab may last longer than 6 months. Reducing the frequency of dosing, or adjusting it according to the monitoring of B‐cell repopulation kinetics in individual patients,20 may maintain efficacy while limiting the risk of infection.24 A similar strategy deserves attention also in view of future vaccinations.25 However, it may not be without risks linked to the re‐expansion of autoreactive B cells.26

The role of interferon treatment and the severity of COVID‐19 is of high interest. Our data indicated a decrease of risk associated with interferon, even if it did not reach statistical significance. The majority of laboratory studies are in line with this preliminary observation, suggesting that supplementing type I interferons may circumvent a defective response that, in people with severe COVID‐19, may depend on various mechanisms including the presence of anti‐interferon autoantibodies,27 a genetically defective type I interferon response,28, 29 or the ability of SARS‐CoV‐2 to neutralize the antiviral effects of type I interferons.30 A recent clinical trial of interferon beta‐1b and lopinavir–ritonavir in Middle East respiratory syndrome31 supports this hypothesis, but a negative trial of interferon beta‐1b, alone or in combination with lopinavir, does not.32 It is possible that timing in the administration of type I interferons is crucial, as early therapy is associated with favorable clinical responses.33 This is in accord with our observation in patients who are already under interferon beta therapy when they develop COVID‐19.

Importantly, methylprednisolone in the month preceding the first symptoms of COVID‐19 was significantly associated with a worse outcome. This aspect was not considered in previous reports, is in agreement with data in other autoimmune diseases,34 and is relevant in assessing the risk of DMTs (ie, COVID‐19 risk vs steroid‐sparing potential).

This study has limitations that must be considered when evaluating the results. First, we included in the study not only confirmed but also suspected cases. For this reason, we cannot exclude that the suspected cases suffered from infections other than COVID‐19. We took the decision of including suspected cases because, during the pandemic peak in Italy, only the most severe cases (often after hospitalization) were tested. Hence, including only confirmed cases would have limited the representativeness of our sample. The inclusion of patients suffering from non–COVID‐19 infections might have diluted the effect of the detected association, resulting in a conservative approach. Furthermore, we reran all the main analyses on the subgroup of confirmed cases, obtaining similar and even stronger results, despite the smaller sample size. A second relevant bias might derive from differences in awareness and expectations of risks in patients receiving therapies with stronger immunosuppressive effect. This might have favored more frequent contacts with treating neurologists, resulting in increased attention to ocrelizumab or rituximab patients. However, the same should have been true also for other intravenous therapies. Finally, although the multivariate analysis adjusts the effect of DMTs on COVID‐19 severity for the main confounding factors, we cannot exclude that some residual confounding can partly explain the observed associations.

Overall, this study shows an acceptable safety profile of DMTs in MS during the COVID‐19 pandemic. The differences that emerged among the various DMTs are in agreement with previous knowledge about infections in PwMS. The results are also plausible based on current biological knowledge, although the exact mechanisms that affect the risk of COVID‐19 remain uncertain. It will be important to look at other ongoing studies35 to verify whether they confirm our findings and to compare the new clinical insight in other autoimmune diseases. This may stimulate new laboratory research and shed new light on the biology of SARS‐CoV‐2 infection and on the pathophysiology of the different autoimmune diseases.

The Musc‐19 Study Group thanks Roche for donating the web‐based platform for data collection and the Department of Informatics, Bioengineering, Robotics, and Systems Engineering, University of Genoa, for its help in installing the platform.

Author Contributions
All authors contributed to the conception and design of the study; the Musc‐19 Study Group contributed to the acquisition and analysis of data; M.P.S., I.S., L.C., and M.S. contributed to drafting the text and preparing the figures.

Potential Conflicts of Interest
M.P.S. reports a grant from Roche to cover data management of this study; Roche makes ocrelizumab, which is one of the DMTs assessed in this study. The remaining authors have nothing to report.

Article source: Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis - Sormani - 2021 - Annals of Neurology - Wiley Online Library

Like this article?

Share on Facebook
Share on Twitter
Share on Linkdin
Share on Email

Jan Campbell


Born in Ōtautahi Jan trained as a nurse in Christchurch, as a midwife in Winchester, UK and has a degree in philosophy with particular interest in healthcare and business ethics.

After working in the public health system in the UK and NZ, Jan joined Roche Pharmaceuticals based in Auckland in 1999. As a respected senior leader and Medical Director, she established a medical division over the ensuing 20 years responsible for significant investment in clinical trials in NZ, developing a top-class global medicine information service, compassionate medicine supply for kiwis in need, pharmacovigilance oversight and a team working closely with patients, specialists, MEDSAFE and PHARMAC to support the safe and appropriate use of Roche medicines.

As a retiree Jan has volunteered for Mercy Hospice in Auckland and the WBoP Museum in Katikati. Now living in Ōtepoti, Jan sits on both the MS Research Trust and MSNZ executive committees with a keen interest to ensure people with MS get a fair go in NZ.

Dr Elza Cloete


Elza is a Neonatal Paediatrician at Christchurch Women’s Hospital. Originally from South Africa, she moved to New Zealand in 2006 and completed her specialist training in Auckland.

Subsequent to that she embarked on doctoral studies at the University of Auckland’s Liggins Institute and obtained a PhD investigating congenital heart disease in new-born babies.

Elza received the Vice-Chancellor’s award for best doctoral thesis for her research and is the author of several research publications. She moved to Christchurch in 2020 for a work opportunity in clinical practice.

Elza was diagnosed with MS in 2012 and brings a consumer perspective and research experience to the Trust.

Kate Russell - ONZM FFINZ


Kate has a thirty year history of working in the community as an enabler, fundraiser, strategic advisor and change maker.

Former CEO of Cystic Fibrosis NZ and the Canterbury Medical Research Foundation, Kate has held many Board positions as well as membership on several government advisory boards such as Pharmac and The Paediatric Society.

Fellow of the Fundraising Institute of NZ, Kate has raised more than 30 million dollars for charity over her career and became an officer of the NZ Order of Merit in 2018 for services to health and governance.

Currently, Partnerships Manager with the ChCh City Council, Kate is a published author and mentors a number of young professionals through Business Mentors NZ and in her spare time, is a marriage celebrant

Kelly Scott


Missing Content!!!

Dr Ernie Willoughby


Dr Willoughby has been a consultant neurologist at Auckland City Hospital (1979 to 2021 – now retired, emeritus) and clinical associate professor at Auckland University School of Medicine.

He directed the MS clinic at Auckland Hospital, has had a long association with the Auckland and NZ MS Societies, and is a member of the International Medical and Scientific Board of the MS International Federation.

Dr Brian Linehan

Independent Trustee

Dr Brian Linehan is a retired pathologist who was previously Managing Director of Medlab Hamilton.

He is currently Chairman of the Tranmere group of investment companies and a Director of a number of other private companies. In 2014, he retired after 12 years on the Council of the University of Waikato where he was Pro-Chancellor.

He is a past Chairman of the New Zealand Medical Association, past Chairman of NZMA Ethics Committee, past President and Chairman of CMAAO (Combined Medical Associations of Asia and Oceania) and past Chairman of IANZ (International Accreditation NZ).

Brian was diagnosed with MS in 2007 but is still active and mobile.

Peter Wood - JP, BCom, AGNZ, ACIS, FNZTA


Peter gained his commerce degree at Victoria University of Wellington and has been practising as a Chartered Accountant initially in Wellington and then in Tauranga.

Peter was a respected and trusted advisor to many businesspeople.
He is now resident in Auckland and consultants to a limited number business clients.

He has also served his community through involvement with Jaycees, Lions and Rotary clubs and a number of charitable trusts.

Peter is currently the Treasurer of Multiple Sclerosis Auckland and a trustee of the Multiple Sclerosis Auckland Trust.
Peter is a Justice of the Peace and a member Governance New Zealand and is a Fellow of the NZ Trustees’ Association.

Malcolm Rickerby


Malcolm is on the National Executive Committee for the Multiple Sclerosis Society of New Zealand. Malcolm is a Past-President both the National Society and the Multiple Sclerosis & Parkinson’s Society of Canterbury.

He is respected for his governance and support for staff in the drive to deliver the best medical outcomes and support for people with Multiple Sclerosis and Parkinson’s as well as keeping them in their communities.

He is a Rotarian and in the forefront of delivering a programme to primary schools to reduce obesity and diabetics in children, called Healthy Heroes, in the 9970 District.

Malcolm has been Chairperson of a High School Board of Governors, secretary, treasurer of a local primary school committee, coached women’s cricket and was a member of Canterbury Women’s Cricket Council. He has also served as a vestryman and vicars warden in the Anglican Christchurch Diocese.

Neil Woodhams


Neil is an independent health management consultant who has had an extensive career in health management as a senior manager or consultant to government, DHBs, primary care and community providers.

Neil is President of MS New Zealand and a trustee of the MS Auckland Region Trust. Neil was also President of MS Auckland until he stepped down from this role mid-2020 to concentrate on his national roles.

Neil’s wife was diagnosed with MS in 1994. One of his four sons was also diagnosed in 2010.

Neil strongly believes in the objectives of the NZ Multiple Sclerosis Research Trust and has advocated for the establishment of the Trust for over 10 years.

Sir William Gallagher


Sir William is renowned as a motivational, pragmatic and hands-on businessman in and outside of New Zealand and has a reputation both as a dynamic leader and one of NZ’s most astute businessmen.

Still very involved in the daily operation, he maintains regular contact with customers in the 130 countries in which Gallagher products are sold spending up to 150 days a year on the road representing the company and its philosophies and emphasising the ethics and integrity of his professional and personal dealings.

His achievements have been officially recognised by a string of awards, the latest to mark his commitment to enterprise and leadership skills being his Knighthood in the 2010 New Year’s Honours List. He was also the 1996 winner of the prestigious Excellence in Communication Leadership award, the first time in its history that it had been awarded outside of North America. He also received an MBE in 1987 followed by a Companion of the New Zealand Order of Merit (CNZM) in 1998.

Sir William Gallagher - KNZM, MBE. HonD


Sir William is renowned as a motivational, pragmatic and hands-on businessman in and outside of New Zealand and has a reputation both as a dynamic leader and one of NZ’s most astute businessmen.

Still very involved in the daily operation, he maintains regular contact with customers in the 130 countries in which Gallagher products are sold spending up to 150 days a year on the road representing the company and its philosophies and emphasising the ethics and integrity of his professional and personal dealings.

His achievements have been officially recognised by a string of awards, the latest to mark his commitment to enterprise and leadership skills being his Knighthood in the 2010 New Year’s Honours List. He was also the 1996 winner of the prestigious Excellence in Communication Leadership award, the first time in its history that it had been awarded outside of North America. He also received an MBE in 1987 followed by a Companion of the New Zealand Order of Merit (CNZM) in 1998.